Literature DB >> 32216487

What is the value of electromagnetic navigation in lung cancer and to what extent does it require improvement?

Brian D Shaller1, Thomas R Gildea1.   

Abstract

INTRODUCTION: Lung nodules are being identified with increasing frequency. With this growing burden of nodules comes a growing need for diagnostic technologies extending beyond the current reach of conventional bronchoscopy. One such method for diagnosing peripheral lung lesions is electromagnetic navigational bronchoscopy (ENB), which comprises a set of tools designed to aid the bronchoscopist in identifying, accessing, and sampling peripheral lung lesions under virtual guidance. AREAS COVERED: Herein we present an in-depth review of ENB, including commercially available electromagnetic navigation platforms, factors influencing diagnostic yield, adjunctive imaging and biopsy tools, potential risks, cost, technical shortcomings, and competing technologies. A review of the scientific literature was conducted primarily through PubMed, ScienceDirect, and Google Scholar, and pertinent publications and abstracts from the inception of electromagnetic navigation through early 2020 were considered. We also share our perspective on the future of ENB from both a diagnostic and a therapeutic standpoint. EXPERT OPINION: ENB is currently a leading tool in the diagnostic evaluation of peripheral lung lesions. The future of ENB rests not only on its potential to expand into the therapeutic realm but also on its ability to keep pace with competing diagnostic and therapeutic technologies.

Entities:  

Keywords:  Electromagnetic navigation bronchoscopy; lung cancer; peripheral lung nodule

Year:  2020        PMID: 32216487     DOI: 10.1080/17476348.2020.1748012

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  1 in total

1.  Cryo-Biopsy versus 19G needle versus 22G needle with EBUS-TBNA endoscopy.

Authors:  Rena Oikonomidou; Dimitris Petridis; Christoforos Kosmidis; Konstantinos Sapalidis; Wolfgang Hohenforst-Schmidt; Vagelis Christakidis; Savas Petanidis; Dimitris Mathaios; Eleni Isidora Perdikouri; Sofia Baka; Christos Tolis; Anastasios Vagionas; Bojan Zaric; Aris Ioannidis; Marios Anemoulis; Konstantinos Porpodis; Vasileios Papadopoulos; Paul Zarogoulidis
Journal:  J Cancer       Date:  2022-08-08       Impact factor: 4.478

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.